{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:12:09Z","timestamp":1792653129157,"version":"4.5.0"},"reference-count":73,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Exome sequencing studies in chronic myelomonocytic leukemia (CMML) illustrate a mutational landscape characterized by few somatic mutations involving a subset of recurrent gene mutations in ASXL1, SRSF2, and TET2, each approaching 40% in incidence. This has led to the clinical implementation of next-generation sequencing panels that effectively identify clonal monocytosis and complement clinical prognostic scoring systems in most patients. However, most murine models based on single gene mutations fail to recapitulate the CMML phenotype, and many gene mutations are loss of function, making the identification of traditional therapeutic vulnerabilities challenging. Further, as a subtype of the myelodysplastic\/myeloproliferative neoplasms, CMML has a complex clinical heterogeneity not reflected by the mutational landscape. In this review, we will discuss the discordance between mutational homogeneity and clinical complexity and highlight novel genomic and nongenomic approaches that offer insight into the underlying clinical characteristics of CMML.<\/jats:p>","DOI":"10.1182\/blood-2016-07-692988","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T03:29:20Z","timestamp":1475724560000},"page":"2381-2387","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia"],"prefix":"10.1182","volume":"128","author":[{"given":"Markus","family":"Ball","sequence":"first","affiliation":[{"name":"Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F.","family":"List","sequence":"additional","affiliation":[{"name":"Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[{"name":"Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111903150593600_B1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"20","key":"2019111903150593600_B2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111903150593600_B3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","article-title":"Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"key":"2019111903150593600_B4","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies","volume":"5","author":"Padron","year":"2015","journal-title":"Blood Cancer J"},{"key":"2019111903150593600_B5","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"issue":"19","key":"2019111903150593600_B6","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111903150593600_B7","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"issue":"7367","key":"2019111903150593600_B8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"14","key":"2019111903150593600_B9","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111903150593600_B10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2015.337","article-title":"Age-related mutations and chronic myelomonocytic leukemia","volume":"30","author":"Mason","year":"2016","journal-title":"Leukemia"},{"issue":"26","key":"2019111903150593600_B11","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111903150593600_B12","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1182\/blood-2003-06-2071","article-title":"Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia","volume":"103","author":"Kindler","year":"2004","journal-title":"Blood"},{"issue":"23","key":"2019111903150593600_B13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.V126.23.323.323","article-title":"Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1\/2 trial [abstract]","volume":"126","author":"Stein","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111903150593600_B14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V126.23.6.6","article-title":"The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)\/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603\/RATIFY [Alliance]) [abstract]","volume":"126","author":"Stone","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111903150593600_B15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V126.23.319.319","article-title":"Addition of sorafenib to chemotherapy improves the overall survival of older adults with FLT3-ITD mutated acute myeloid leukemia (AML)(Alliance C11001) [abstract]","volume":"126","author":"Uy","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111903150593600_B16","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood.V120.21.1712.1712","article-title":"A close association of history of autoimmunity with chronic myelomonocytic leukemia (CMML) in contrast to chronic myelogenous leukemia (CML) [abstract]","volume":"120","author":"Peker","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111903150593600_B17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"15","key":"2019111903150593600_B18","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111903150593600_B19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V114.22.290.290","article-title":"Chronic myelomonocytic leukemia (CMML) with more than 15% of ring sideroblasts in bone marrow: an overlapping disorder between CMML and refractory anemia with ring sideroblasts [abstract]","volume":"114","author":"Such","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2019111903150593600_B20","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"issue":"15","key":"2019111903150593600_B21","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-15-2781","article-title":"A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML)","volume":"22","author":"Padron","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111903150593600_B22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.leukres.2011.05.003","article-title":"Cutaneous manifestations in CMML: indication of disease acceleration or transformation to AML and review of the literature","volume":"36","author":"Mathew","year":"2012","journal-title":"Leuk Res"},{"issue":"4","key":"2019111903150593600_B23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejim.2005.09.027","article-title":"Unusual skin and testicular lesions in a patient with CMML","volume":"17","author":"Dyachenko","year":"2006","journal-title":"Eur J Intern Med"},{"issue":"7","key":"2019111903150593600_B24","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes [published correction appears in Leukemia. 2013;27(10):2112]","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"issue":"15","key":"2019111903150593600_B25","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"7457","key":"2019111903150593600_B26","first-page":"214","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature","volume":"499","author":"Lawrence","year":"2013"},{"issue":"8","key":"2019111903150593600_B27","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ng.2696","article-title":"Somatic SETBP1 mutations in myeloid malignancies","volume":"45","author":"Makishima","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"2019111903150593600_B28","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/bcj.2014.94","article-title":"Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia","volume":"5","author":"Lasho","year":"2015","journal-title":"Blood Cancer J"},{"issue":"21","key":"2019111903150593600_B29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood.V116.21.296.296","article-title":"Analyses of 81 chronic myelomonocytic leukemia (CMML) for EZH2, TET2, ASXL1, CBL, KRAS, NRAS, RUNX1, IDH1, IDH2, and NPM1 revealed mutations in 86.4% of all patients with TET2 and EZH2 being of high prognostic relevance [abstract]","volume":"116","author":"Grossmann","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111903150593600_B30","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111903150593600_B31","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111903150593600_B32","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/leu.2008.162","article-title":"Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia","volume":"22","author":"Emanuel","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"2019111903150593600_B33","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2014-09-601690","article-title":"Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia","volume":"125","author":"Stieglitz","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2019111903150593600_B34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.2698","article-title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia","volume":"45","author":"Sakaguchi","year":"2013","journal-title":"Nat Genet"},{"issue":"23","key":"2019111903150593600_B35","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111903150593600_B36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111903150593600_B37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"issue":"7382","key":"2019111903150593600_B38","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"8","key":"2019111903150593600_B39","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.2015.9643","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia","volume":"314","author":"Klco","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"2019111903150593600_B40","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.29145","article-title":"Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"issue":"281","key":"2019111903150593600_B41","doi-asserted-by":"crossref","first-page":"281re2","DOI":"10.1126\/scitranslmed.aaa0763","article-title":"Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia","volume":"7","author":"Paguirigan","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"2019111903150593600_B42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"issue":"26","key":"2019111903150593600_B43","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1182\/blood-2010-04-281527","article-title":"Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic\/monocytic precursors in a murine model of chronic myelomonocytic leukemia","volume":"116","author":"Wang","year":"2010","journal-title":"Blood"},{"issue":"7257","key":"2019111903150593600_B44","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"issue":"21","key":"2019111903150593600_B45","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood.V124.21.824.824","article-title":"SRSF2 mutations impair hematopoietic differentiation by altering exonic splicing enhancer preference [abstract]","volume":"124","author":"Kim","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111903150593600_B46","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1084\/jem.20131141","article-title":"Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo","volume":"210","author":"Abdel-Wahab","year":"2013","journal-title":"J Exp Med"},{"issue":"7346","key":"2019111903150593600_B47","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature09999","article-title":"A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia","volume":"473","author":"Klinakis","year":"2011","journal-title":"Nature"},{"issue":"4","key":"2019111903150593600_B48","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cell.2013.01.034","article-title":"Xist RNA is a potent suppressor of hematologic cancer in mice","volume":"152","author":"Yildirim","year":"2013","journal-title":"Cell"},{"issue":"9","key":"2019111903150593600_B49","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1182\/blood-2010-02-267906","article-title":"Reduced NR4A gene dosage leads to mixed myelodysplastic\/myeloproliferative neoplasms in mice","volume":"117","author":"Ramirez-Herrick","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111903150593600_B50","doi-asserted-by":"crossref","first-page":"e51228","DOI":"10.1371\/journal.pone.0051228","article-title":"Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice","volume":"7","author":"Lamothe","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"2019111903150593600_B51","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"7325","key":"2019111903150593600_B52","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"issue":"7","key":"2019111903150593600_B53","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nm.4125","article-title":"Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia","volume":"22","author":"Li","year":"2016","journal-title":"Nat Med"},{"issue":"5","key":"2019111903150593600_B54","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1172\/JCI78752","article-title":"Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia","volume":"125","author":"Meldi","year":"2015","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111903150593600_B55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12185-009-0375-5","article-title":"Chronic inflammatory demyelinating polyneuropathy accompanied by chronic myelomonocytic leukemia: possible pathogenesis of autoimmunity in myelodysplastic syndrome","volume":"90","author":"Isoda","year":"2009","journal-title":"Int J Hematol"},{"issue":"6","key":"2019111903150593600_B56","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/ejh.12393","article-title":"Immune thrombocytopenia in chronic myelomonocytic leukemia","volume":"93","author":"Hadjadj","year":"2014","journal-title":"Eur J Haematol"},{"issue":"4","key":"2019111903150593600_B57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10792-012-9675-5","article-title":"A diagnostic challenge: chronic myelomonocytic leukaemia and recurrent anterior ischaemic optic neuropathy","volume":"33","author":"De Smit","year":"2013","journal-title":"Int Ophthalmol"},{"key":"2019111903150593600_B58","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.leukres.2016.05.013","article-title":"Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: a series of 26 cases and literature review","volume":"47","author":"Grignano","year":"2016","journal-title":"Leuk Res"},{"key":"2019111903150593600_B59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.leukres.2016.02.005","article-title":"Efficacy of azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"43","author":"Fraison","year":"2016","journal-title":"Leuk Res"},{"issue":"23","key":"2019111903150593600_B60","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"issue":"25","key":"2019111903150593600_B61","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111903150593600_B62","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0301-472X(02)00903-7","article-title":"Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo","volume":"30","author":"Ramshaw","year":"2002","journal-title":"Exp Hematol"},{"issue":"4","key":"2019111903150593600_B63","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccr.2008.08.014","article-title":"Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates","volume":"14","author":"Kotecha","year":"2008","journal-title":"Cancer Cell"},{"issue":"12","key":"2019111903150593600_B64","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111903150593600_B65","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111903150593600_B66","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111903150593600_B67","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ccell.2015.04.008","article-title":"Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo","volume":"27","author":"Shirai","year":"2015","journal-title":"Cancer Cell"},{"key":"2019111903150593600_B68","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.1038\/ncomms7042","article-title":"Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome","volume":"6","author":"Madan","year":"2015","journal-title":"Nat Commun"},{"issue":"6","key":"2019111903150593600_B69","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nm.4097","article-title":"Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins","volume":"22","author":"Lee","year":"2016","journal-title":"Nat Med"},{"issue":"11","key":"2019111903150593600_B70","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2019111903150593600_B71","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.molcel.2012.05.014","article-title":"The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus","volume":"47","author":"Zhou","year":"2012","journal-title":"Mol Cell"},{"issue":"21","key":"2019111903150593600_B72","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1182\/blood.V122.21.2772.2772","article-title":"JAK2 dependent GM-CSF signaling triggers SRSF2 phosphorylation: a potential cause of mutation-independent RNA splicing aberrancy in CMML [abstract]","volume":"122","author":"Kunigal","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111903150593600_B73","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/20\/2381\/1397240\/blood692988.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/20\/2381\/1397240\/blood692988.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T08:15:34Z","timestamp":1574151334000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/20\/2381\/35620\/When-clinical-heterogeneity-exceeds-genetic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,17]]},"references-count":73,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2016,11,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-07-692988","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,17]]}}}